Value of mid-regional pro-atrial natriuretic peptide and brain natriuretic peptide for detection of acute heart failure in patients with dyspnea: diagnostic accuracy study
Iranian Journal of Emergency Medicine,
Vol. 10 No. 1 (2023),
30 November 2022
Background: The measurement of mid-regional pro-atrial natriuretic peptide (MR-proANP) as a clinical biomarker has become a potent diagnostic value for identifying patients with heart failure. This study aimed to determine the diagnostic value of MR-proANP in heart failure in comparison with brain natriuretic peptide (BNP).
Methods: This prospective diagnostic accuracy study evaluated two biomarkers in consecutive patients presenting to the emergency department (ED) with acute dyspnea. Blood samples were collected immediately from the participants. A diagnostic value of MR-proANP versus BNP for the diagnosis of acute heart failure was analyzed. All patients underwent transthoracic echocardiography to classify the diagnosis as dyspnea due to heart failure or due to other causes. Patients without a subsequent diagnosis of heart failure were compared as the controls. The diagnostic performance was evaluated by receiver operating characteristics (ROC) analysis.
Results: Overall, 100 patients with heart failure and 85 controls were included in the study. The plasma levels of BNP and MR-proANP were significantly higher in the heart failure patients than in the control patients (p<0.001). MR-proANP levels significantly correlated with BNP levels (r=0.745, p<0.001). The ROC analysis demonstrated an area under the curve (AUC) of 0.872 (95% CI: 0.815–0.917) for MR-proANP and an AUC of 0.814 (95% CI: 0.751–0.868) for BNP. The AUC of MR-proANP was significantly higher than BNP to detect heart failure in patients with dyspnea (p=0.008). The optimal cut-off point of plasma MR-proANP was 134 pmol/L (sensitivity: 88.1%; specificity: 84.5%; PPV: 87.3%; NPV: 85.5%).
Conclusion: MR-proANP may be a useful biomarker for the diagnosis of acute heart failure in patients with dyspnea presenting to ED. The diagnostic value of MR-proANP was superior to BNP for diagnosing heart failure.
- Natriuretic peptide
- Heart failure
How to Cite
Farazmand A, Toloei M. Causes of patients’ hospitalization in Guilan university hospitals. Guilan Univ Med Sci. 2002;11(42):28-32.
Habibi A, Nikpour S, Seiedoshohadaei M, Haghani H. Quality of life and status of physical functioning among elderly people in west region of Tehran: a cross-sectional survey. Iran J Nurs. 2008;21(53):29-39.
Gohar A, Rutten FH, den Ruijter H, Kelder JC, von Haehling S, Anker SD, et al. Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure. Eur J Heart Fail. 2019;21(10):1219-27.
van Riet EE, Hoes AW, Limburg A, Landman MA, van der Hoeven H, Rutten FH. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail. 2014;16(7):772-7.
Razavi-Kia M, Ansari M. Patients pivoted nursing rehabilitation for older people with dementia. Arch of Rehab. 2007;8(1):79-86.
Seino Y, Ogawa A, Yamashita T, Fukushima M, Ogata K, Fukumoto H, et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail. 2004;6(3):295-300.
Chen AA, Wood MJ, Krauser DG, Baggish AL, Tung R, Anwaruddin S, et al. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J. 2006;27(7):839-45.
Omar AMS, Bansal M, Sengupta PP. Advances in echocardiographic imaging in heart failure with reduced and preserved ejection fraction. Circ Res. 2016;119(2):357-74.
Bytyçi I, Bajraktari G. Left atrial changes in early stages of heart failure with preserved ejection fraction. Echocardiography. 2016;33(10):1479-87.
Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715-31.
Cui K, Huang W, Fan J, Lei H. Midregional pro-atrial natriuretic peptide is a superior biomarker to N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction. Medicine (Baltimore). 2018;97(36):e12277.
Rørth R, Jhund PS, Yilmaz MB, Kristensen SL, Welsh P, Desai AS, et al. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020;13(2):e006541.
Oremus M, Don-Wauchope A, McKelvie R, Santaguida PL, Hill S, Balion C, et al. BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure. Heart Fail Rev. 2014;19(4):471-505.
Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;55(19):2062-76.
Idzikowska K, Zielińska M. Midregional pro-atrial natriuretic peptide, an important member of the natriuretic peptide family: potential role in diagnosis and prognosis of cardiovascular disease. J Int Med Res. 2018;46(8):3017-29.
Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2(5):358-67.
Heining L, Giesa C, Ewig S. MR-proANP, MR-proADM, and PCT in Patients Presenting with Acute Dyspnea in a Medical Emergency Unit. Lung. 2016;194(2):185-91.
Darche FF, Baumgärtner C, Biener M, Müller-Hennessen M, Vafaie M, Koch V, et al. Comparative accuracy of NT-proBNP and MR-proANP for the diagnosis of acute heart failure in dyspnoeic patients. ESC Heart Fail. 2017;4(3):232-40.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726.
Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart. 2009;95(18):1508-13.
Gegenhuber A, Struck J, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, et al. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clin Chem. 2006;52(5):827-31.
Potocki M, Breidthardt T, Reichlin T, Hartwiger S, Morgenthaler NG, Bergmann A, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. J Intern Med. 2010;267(1):119-29.
Clerico A, Fontana M, Zyw L, Passino C, Emdin M. Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clin Chem. 2007;53(5):813-22.
Daniels LB, Clopton P, Potocki M, Mueller C, McCord J, Richards M, et al. Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. Eur J Heart Fail. 2012;14(1):22-31.
Rutjes AW, Reitsma JB, Vandenbroucke JP, Glas AS, Bossuyt PM. Case-control and two-gate designs in diagnostic accuracy studies. Clin Chem. 2005;51(8):1335-41.
- Abstract Viewed: 42 times
- pdf Downloaded: 39 times